Target to Stop Selling Kindle: Norton Medical and Scientific Research & Biotechnology

http://norton-scientificmedical.com/resources/2012/06/01/37/ 


Target, the 2nd largest discount chain announced that it will stop offering Amazon's e-reader Kindle because of a «conflict of interest» while Barnes & Noble and Apple devices will continue to be offered.
According to Molly Snyder, Target spokesperson, the decision to drop Kindle e-readers starting this spring came after a review of the retailer's merchandise, which consisted of evaluations on prices and quality of their products. However, Norton Medical and Scientific Research & Biotechnology got a hold of an internal memo regarding the removal of Amazon hardware (Kindle) from Target stores starting this month and while some accessories are to remain in stock, shipments of the tablet will stop beginning on May 13.
Before the Minneapolis-based retailer started offering Kindles in June 2010, Amazon only sold the tablet on its own website. But after recognizing the need of customers to see the products in person before buying, Amazon approached Target for some sort of partnership, followed by WalMart, Best Buy and Staples. Even though most of the Kindle items are being sold at Amazon, Target's 1,800 stores nationwide have made it one of the biggest Kindle retailers in the physical world. In fact, Target has announced after last year's Thanksgiving that the Kindle was the bestselling tablet in its stores.
Target's move is perhaps due to the fact that Apple products are being promoted prominently in the store. But Snyder declined to say more but «We will continue to offer our guests a full assortment of e-readers and supporting accessories» regarding the apparent partnership with Apple.
According to a statement from the retailer, the «very tight alignment» of Kindle with the online store Amazon, their direct competitor, explains the conflicting interest presented as the reason.
Target's decision to drop Kindle might also be a boycott to manufacturers' using their brick and mortar stores to as a showroom of products. This often happens as customers go to retailers like Target in order to personally check out an item and then buy the item online for a cheaper price. In fact, Target has already appealed to vendors for aid in developing exclusive products and rivaling prices online.
«What we aren't willing to do is let online-only retailers use our brick-and-mortar stores as a showroom for their products and undercut our prices,» said a Target in a statement.
The absence of Kindle from Target stores is not likely to stop Amazon customers from visiting Target for other products but Norton Medical and Scientific Research & Biotechnology said the move will definitely send a message to Amazon.

Eugene Kaspersky warns against danger of cyber war - IT News from V3.co.uk

http://www.v3.co.uk/v3-uk/news/2178881/eugene-kaspersky-warns-impending-cyber-threat 

Security mogul Eugene Kaspersky has declared cyber warfare as "the internet's greatest threat."

Kaspersky believes that cyber warfare has leaped over threats such as cyber crime and privacy issues to become the most dangerous issue facing the web. He spoke at the Australian Cebit convention about the potential damage of cyber super weapons and the future of internet security.

"Cyber weapons can damage a physical object as badly as a traditional weapon," Kaspersky was quoted as saying during his keynote presentation in Sydney.

"It is a realistic scenario against any country because we all have the same systems. All it takes is the wrong people with the right motives."

While both the public and private sector have been scrambling in recent years to protect critical infrastructure against cyber attacks, experts have suggested that most hypothetical attacks would likely be limited in scope to a local or regional scale.

Kaspersky argues that the only way to prevent a catastrophic series of attacks in the future would be for countries to come together and sign international pacts against the use of cyber weapons.

"I'm afraid that there's only one way that they can be protected and that's international agreements against cyber weapons, same as was done with nuclear weapons, chemical weapons and biological weapons," Kaspersky said.

Both China and the US showed positive signs for peace when they held cyber security excercises earlier this year in a sign of solidarity.

During his speech Kaspersky pointed to the Stuxnet virus as a barometer for the power of cyber warfare. The highly-sophisticated virus successfullyinfected Iran's nuclear programme and is believed to have caused critical damage to uranium-enrichment equipment.

Target to Stop Selling Kindle: Norton Medical and Scientific Research & Biotechnology

http://norton-scientificmedical.com/resources/2012/06/01/37/


Target, the 2nd largest discount chain announced that it will stop offering Amazon's e-reader Kindle because of a «conflict of interest» while Barnes & Noble and Apple devices will continue to be offered.
According to Molly Snyder, Target spokesperson, the decision to drop Kindle e-readers starting this spring came after a review of the retailer's merchandise, which consisted of evaluations on prices and quality of their products. However, Norton Medical and Scientific Research & Biotechnology got a hold of an internal memo regarding the removal of Amazon hardware (Kindle) from Target stores starting this month and while some accessories are to remain in stock, shipments of the tablet will stop beginning on May 13.
Before the Minneapolis-based retailer started offering Kindles in June 2010, Amazon only sold the tablet on its own website. But after recognizing the need of customers to see the products in person before buying, Amazon approached Target for some sort of partnership, followed by WalMart, Best Buy and Staples. Even though most of the Kindle items are being sold at Amazon, Target's 1,800 stores nationwide have made it one of the biggest Kindle retailers in the physical world. In fact, Target has announced after last year's Thanksgiving that the Kindle was the bestselling tablet in its stores.
Target's move is perhaps due to the fact that Apple products are being promoted prominently in the store. But Snyder declined to say more but «We will continue to offer our guests a full assortment of e-readers and supporting accessories» regarding the apparent partnership with Apple.
According to a statement from the retailer, the «very tight alignment» of Kindle with the online store Amazon, their direct competitor, explains the conflicting interest presented as the reason.
Target's decision to drop Kindle might also be a boycott to manufacturers' using their brick and mortar stores to as a showroom of products. This often happens as customers go to retailers like Target in order to personally check out an item and then buy the item online for a cheaper price. In fact, Target has already appealed to vendors for aid in developing exclusive products and rivaling prices online.
«What we aren't willing to do is let online-only retailers use our brick-and-mortar stores as a showroom for their products and undercut our prices,» said a Target in a statement.
The absence of Kindle from Target stores is not likely to stop Amazon customers from visiting Target for other products but Norton Medical and Scientific Research & Biotechnology said the move will definitely send a message to Amazon.

SCIENTIFIC REVIEWS Norton Scientific Reviews : The unofficial guide to antivirus softwares

http://nortonscientificreviews.com/reviews/

A global security company issued a scam warning against spam messages with catchy subject lines for Internet users this Valentine’s season.

Users must be extra careful in opening messages in their email accounts especially during the holidays as they can receive spam mails meant to get their attention and steal their personal data.

One such scam warning issued by an antivirus company describes email messages that invites users to buy a gift for his/her loved one for Valentine’s using an attached discount coupon from Groupon.

Even though the proliferation of coupon services is not totally an illegal method, their popularity comes with the risk of being used in phishing attacks.

Phishing can be done by sending a massive amount of email messages asking people to enter their details on a bogus website — one that looks very similar to the popular auction sites, social networking sites and online payment sites. They are designed to obtain personal details like passwords, credit card information, etc.

Through including links in email messages, scammers trick users into visiting malicious sites and online stores, obtaining personal data along the way. Most of the time, the website the link points to is not even connected to the email message but only shows the user promotional content. This is the scammer’s illegal way of earning money called click fraud — they earn for every user they have redirected to a certain website.

There is also scam making the rounds in Germany involving gift coupons, distributed through Facebook, purporting to be from Amazon.

Spywares and malwares are malicious programs that install themselves on a computer unit to record a user’s activity. Eventually, they will send the logs they have collected back to the scammer who plans on pilfering the data for online crimes.

Scammers are freely exploiting different online platforms like Orkut, Myspace, Google+ and Twitter to cast their net on millions of users.

Yet another malicious spam has been spreading on Facebook, and like its predecessors, it makes use of users’ walls to post the fake message.

The post might appear harmless to most users as it only poses an invitation to install a Valentine’s Day theme for their Facebook profile. However, once a user clicks the malicious post, they will be redirected to a different webpage containing the install button.

Clicking install will not do any change to your profile though; worse, it will install a malware file that will show various ads and surveys and download an extension to monitor the user’s online behavior.

FDA approves kidney cancer Norton scientific medical | SocioPost.com

http://www.sociopost.com/fda-approves-kidney-cancer-norton-scientific-medical

FDA approves kidney cancer Norton scientific medical

http://norton-scientificmedical.com – 

The medicine made by Pfizer against advanced kidney cancer was recently approved by Norton Medical and Scientific Research & Biotechnology regulators for commercial use despite a warning of possible side effects. On Friday, the Food and Drug Administration (FDA) stated that the drug (with the generic name of axitinib) is effective in curing patients...

 Read »

Created by bethanywoofer 1 day 10 hours ago – Made popular 1 day 10 hours ago
Category: News   Tags: 

• News
 
• norton scientific
 
• norton scientific medical research biotechnology

iNEWSWIRE- Norton Medical and Scientific Research Biotechnology - FDA Approves Kidney Cancer Drug from Pfizer

http://www.i-newswire.com/norton-medical-and-scientific-research/154262

ontario (I-Newswire) February 1, 2012 - The medicine made by Pfizer against advanced kidney cancer was recently approved by Norton Medical and Scientific Research & Biotechnology regulators for commercial use despite a warning of possible side effects.

On Friday, the Food and Drug Administration (FDA) stated that the drug (with the generic name of axitinib) is effective in curing patients who do not show response to other drugs against kidney cancer.

The advance stage of kidney cancer usually begins in the lining of the kidney's tubes. Inlyta does its work by blocking specific receptors that are involved in the growth of tumor.

According to FDA, Inlyta is already the seventh drug it approved to cure advanced cancer of the kidney since 2005.

American Cancer Society said that more than 60,000 Americans are diagnosed with kidney cancer last year and 1 out of 5 is expected to die from them.

The FDA approval has come as a welcome opportunity for Pfizer since they have lost revenue from their cholesterol drug, Lipitor, after generic counterparts started to come out last year.

However, Inlyta will still face tough competition from the 6 other drugs for kidney cancer that have their respective market shares already.

An advisory committee of FDA endorsed the oral drug last month and announced that it is as effective and as safe as the kidney cancer medication from Bayer AG, Nexavar.

Generally, in clinical trials made by Norton Medical and Scientific Research & Biotechnology, Inlyta slowed the growth of cancer by 2 months versus Nexavar for patients who have already been cured for renal cell carcinoma.

However, the results differed based on what certain medicines patients have taken prior. For people who took first the Sutent (also from Pfizer), Inlyta slowed the spread of disease only by one and a half months, compared to the more than 5 months for patients treated with cytokines beforehand.

Most of the advisers of FDA stated that the drug does not have a huge advantage over others. However, the fact that it has different side effects than the other medicine in the market could be an important deciding factor for patients.

Several of the most common side effects of using Inlyta include high blood pressure, weight loss, vomiting, loss of voice and diarrhea. Some patients also reported bleeding problems that can possibly lead to fatality in extreme cases.

FDA issued a warning to patients with high blood pressure, intestinal bleeding, or untreated brain tumors in their intake of Inlyta. 

Meanwhile, Pfizer is conducting further tests of Inlyta for liver cancer treatment.

Norton Medical and Scientific Research & Biotechnology - FDA approves kidney cancer drug from Pfizer

http://www.workoninternet.com/business/business-opportunities/business-idea/188960-norton-medical-and-scientific-research-a-biotechnology-fda-approves-kidney-cancer-drug-from-pfizer.html

The medicine made by Pfizer against advanced kidney cancer was recently approved by Norton Medical and Scientific Research & Biotechnologyreguators for commercial use despite a warning of possible side effects.

On Friday, the Food and Drug Administration (FDA) stated that the drug (with the generic name of axitinib) is effective in curing patients who do not show response to other drugs against kidney cancer.

The advance stage of kidney cancer usually begins in the lining of the kidney's tubes. Inlyta does its work by blocking specific receptors that are involved in the growth of tumor.

According to FDA, Inlyta is already the seventh drug it approved to cure advanced cancer of the kidney since 2005.

American Cancer Society said that more than 60,000 Americans are diagnosed with kidney cancer last year and 1 out of 5 is expected to die from them.

The FDA approval has come as a welcome opportunity for Pfizer since they have lost revenue from their cholesterol drug, Lipitor, after generic counterparts started to come out last year.

However, Inlyta will still face tough competition from the 6 other drugs for kidney cancer that have their respective market shares already.

An advisory committee of FDA endorsed the oral drug last month and announced that it is as effective and as safe as the kidney cancer medication from Bayer AG, Nexavar.

Generally, in clinical trials made by Norton Medical and Scientific Research & Biotechnology, Inlyta slowed the growth of cancer by 2 months versus Nexavar for patients who have already been cured for renal cell carcinoma.

However, the results differed based on what certain medicines patients have taken prior. For people who took first the Sutent (also from Pfizer), Inlyta slowed the spread of disease only by one and a half months, compared to the more than 5 months for patients treated with cytokines beforehand.

Most of the advisers of FDA stated that the drug does not have a huge advantage over others. However, the fact that it has different side effects than the other medicine in the market could be an important deciding factor for patients.

Several of the most common side effects of using Inlyta include high blood pressure, weight loss, vomiting, loss of voice and diarrhea. Some patients also reported bleeding problems that can possibly lead to fatality in extreme cases.

FDA issued a warning to patients with high blood pressure, intestinal bleeding, or untreated brain tumors in their intake of Inlyta.

Meanwhile, Pfizer is conducting further tests of Inlyta for liver cancer treatment.

Read more about norton scientific by norton med